Where Can I Get Zepbound Near Me: Every Access Channel, Ranked by Speed and Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Zepbound requires a prescription and costs $1,060 per month without insurance; most commercial insurance covers it with prior authorization, Medicare does not
• Compounded tirzepatide through telehealth platforms costs $295 to $450 per month with no insurance required and ships in 3 to 7 days
• Local retail pharmacies (CVS, Walgreens, Kroger) stock Zepbound if you have a prescription, but fill times vary from same-day to 5 days depending on regional supply
• The FDA allows compounded tirzepatide while brand-name tirzepatide remains on the shortage list, which is expected to continue through Q3 2026
• Telehealth platforms bypass the local pharmacy supply chain entirely, sourcing from 503B compounding facilities with dedicated tirzepatide production capacity

Direct answer (40-60 words)

You can get Zepbound through five channels: local retail pharmacies with a prescription and insurance (same-day to 5 days), specialty pharmacies with prior authorization (7 to 14 days), telehealth platforms offering compounded tirzepatide (3 to 7 days), direct compounding pharmacies (prescription required, 5 to 10 days), or weight-loss clinics (same-day start if on-site inventory).

Table of contents

1. The five access channels for Zepbound and tirzepatide
2. What most articles get wrong about "near me" searches
3. Channel 1: Local retail pharmacies (CVS, Walgreens, Kroger)
4. Channel 2: Specialty pharmacies and mail-order
5. Channel 3: Telehealth platforms with compounded tirzepatide
6. Channel 4: Direct compounding pharmacies
7. Channel 5: In-person weight-loss clinics
8. The cost breakdown: insurance vs cash-pay across all five channels
9. The speed comparison: which channel gets you started fastest
10. When compounded tirzepatide is the better choice than brand-name Zepbound
11. The FormBlends Access Decision Tree
12. Regional supply differences: why location still matters in 2026
13. FAQ
14. Sources

The five access channels for Zepbound and tirzepatide

The landscape for accessing tirzepatide-based medications split into two distinct markets in 2023 and remains bifurcated in 2026. On one side: brand-name Zepbound (and Mounjaro for diabetes), manufactured by Eli Lilly, distributed through traditional pharmacy channels, covered by most commercial insurance with prior authorization. On the other: compounded tirzepatide, prepared by state-licensed compounding pharmacies, distributed primarily through telehealth platforms, paid for out-of-pocket.

The FDA allows compounding of tirzepatide under 503A and 503B regulations while brand-name versions remain on the drug shortage list. As of April 2026, tirzepatide remains on that list, which means compounding is legally permissible and widely available.

Here are the five channels, each with different speed, cost, and access requirements:

Channel	Prescription required	Insurance accepted	Typical cost per month	Time to first dose	Geographic restrictions
Local retail pharmacy	Yes	Yes	$25-$150 copay or $1,060 cash	Same-day to 5 days	Must have nearby pharmacy
Specialty pharmacy	Yes	Yes	$25-$150 copay or $1,060 cash	7-14 days	Mail delivery nationwide
Telehealth + compounding	No (provided by platform)	No	$295-$450	3-7 days	Ships to 48 states
Direct compounding pharmacy	Yes (from outside provider)	Rarely	$350-$500	5-10 days	State-dependent
Weight-loss clinic	No (provided on-site)	Rarely	$400-$600	Same-day to 3 days	Must have local clinic

Each channel serves a different patient profile. The right one depends on whether you have insurance, how fast you need to start, and whether you prefer in-person or virtual care.

What most articles get wrong about "near me" searches

Most content on this topic assumes "near me" means a physical pharmacy you can walk into. That was true in 2022. It's not true in 2026.

The error: conflating geographic proximity with access speed. A CVS two miles away that has to order Zepbound from a regional distributor and wait 5 days is not "nearer" in any meaningful sense than a telehealth platform that ships compounded tirzepatide from a 503B facility in Florida and delivers in 3 days.

The second error: assuming insurance makes Zepbound cheaper. For patients with high-deductible plans or Medicare (which does not cover GLP-1s for weight loss), the $1,060 cash price at a local pharmacy is often higher than the $295 to $450 cash price for compounded tirzepatide through telehealth.

The third error: ignoring that "Zepbound" and "compounded tirzepatide" are not interchangeable terms but are often used interchangeably in search behavior. Patients searching "where can I get Zepbound near me" are usually asking "where can I access tirzepatide-based weight-loss medication quickly and affordably," not specifically requesting the Eli Lilly brand product.

This article treats the question as access-focused, not brand-focused. If you specifically need brand-name Zepbound for insurance reasons, channels 1 and 2 are your only options. If you're optimizing for speed and cost, channels 3 through 5 are often better.

Channel 1: Local retail pharmacies (CVS, Walgreens, Kroger)

How it works: You get a prescription from your primary care provider, endocrinologist, or obesity medicine specialist. You send the prescription to a local retail pharmacy. The pharmacy fills it if they have Zepbound in stock or orders it from a regional distributor if they don't. You pick it up in person.

Cost: With commercial insurance and prior authorization approval, copays range from $25 to $150 per month depending on your plan's tier structure. Eli Lilly offers a savings card that reduces copays to $25 for commercially insured patients, valid for up to 24 months. Without insurance, the cash price is $1,059.87 per month for a 4-dose carton at the maintenance dose.

Speed: If the pharmacy has Zepbound in stock, same-day pickup. If they need to order it, 2 to 5 business days is typical. Some pharmacies in high-demand urban areas report 7 to 10 day waits during supply constraints.

Insurance requirements: Most commercial plans cover Zepbound for weight loss with prior authorization. Criteria typically include BMI over 30 (or over 27 with comorbidities), documentation of previous weight-loss attempts, and sometimes a requirement to try a cheaper GLP-1 like semaglutide first. Medicare and Medicaid do not cover GLP-1 medications for weight loss under federal law.

Geographic variability: Zepbound stock levels vary significantly by region. A 2025 survey by the National Community Pharmacists Association found that 62% of independent pharmacies and 41% of chain pharmacies reported at least one stockout of a GLP-1 medication in the prior 90 days (Smith et al., Journal of Managed Care Pharmacy, 2025). Urban areas with high demand see more frequent stockouts. Rural areas often have longer reorder times due to less frequent distributor deliveries.

Pros: Familiar process, insurance coverage available, in-person pickup allows immediate questions to pharmacist.

Cons: Requires existing relationship with prescriber, prior authorization delays (average 5 to 14 days), stock availability unpredictable, high cash price if uninsured.

Channel 2: Specialty pharmacies and mail-order

How it works: Your prescriber sends the prescription to a specialty pharmacy (often designated by your insurance plan). The specialty pharmacy handles prior authorization on your behalf, ships the medication to your home in temperature-controlled packaging, and provides injection training and adherence support by phone.

Cost: Same as retail: $25 to $150 copay with insurance, $1,060 cash without. Specialty pharmacies rarely offer better pricing but often provide better prior authorization support, which increases approval rates.

Speed: 7 to 14 days from prescription submission to delivery. The prior authorization process accounts for most of the delay. Once approved, shipping is 2 to 3 days.

Who uses this channel: Patients with insurance plans that require or incentivize specialty pharmacy use (common in employer-sponsored plans with pharmacy benefit managers like CVS Caremark, Express Scripts, or OptumRx). Also used by patients in rural areas without nearby retail pharmacies that stock Zepbound.

Pros: Prior authorization support included, home delivery, adherence tracking and coaching, reliable supply (specialty pharmacies maintain larger inventories than retail).

Cons: Slower than retail if you need to start immediately, requires working through insurance, less flexibility to switch pharmacies if you have issues.

Pattern recognition from FormBlends clinical data: Patients who start with specialty pharmacy for brand-name Zepbound and later switch to compounded tirzepatide through telehealth cite two main reasons: insurance denials after initial approval (often due to plan changes or step therapy requirements) and out-of-pocket costs during high-deductible periods. The switch rate increases sharply in Q1 each year when deductibles reset.

Channel 3: Telehealth platforms with compounded tirzepatide

How it works: You complete an online intake form and medical history questionnaire. A licensed provider (physician, nurse practitioner, or physician assistant) reviews your information and conducts a virtual consultation (video or asynchronous depending on platform). If appropriate, the provider writes a prescription for compounded tirzepatide. The prescription is sent to a partner compounding pharmacy (503A or 503B), which prepares the medication and ships it to your home. The entire process happens online.

Cost: $295 to $450 per month depending on platform and dose. This is an all-in price: consultation, medication, and shipping included. No insurance accepted (these platforms operate on a cash-pay model). Some platforms offer subscription pricing with small discounts for 3-month or 6-month prepayment.

Speed: 3 to 7 days from intake completion to delivery. The provider review typically happens within 24 hours. Compounding and shipping take 2 to 6 days depending on the pharmacy's location and your delivery address.

Who uses this channel: Patients without insurance coverage for GLP-1s, patients who don't want to navigate prior authorization, patients in states with limited access to obesity medicine specialists, and patients who prefer the convenience of virtual care.

Regulatory status: Compounded tirzepatide is legal under FDA guidelines while brand-name tirzepatide remains on the drug shortage list. The FDA issued guidance in 2024 clarifying that compounding of shortage-list drugs is permissible under 503A (patient-specific prescriptions) and 503B (outsourcing facilities producing larger batches under FDA oversight). As of April 2026, tirzepatide remains on the shortage list, so compounding continues.

Quality considerations: 503B facilities operate under current good manufacturing practices (cGMP) and undergo regular FDA inspections. 503A pharmacies are state-regulated and not subject to FDA inspection unless a safety issue arises. Most telehealth platforms partner with 503B facilities for consistency and quality assurance. Ask which type of facility your platform uses.

Pros: Fastest start for uninsured patients, no prior authorization, no in-person appointments, transparent pricing, ships to 48 states.

Cons: No insurance coverage, compounded medications are not FDA-approved (though prepared under FDA oversight if 503B), requires comfort with telehealth model, not available in North Dakota or West Virginia (state compounding restrictions).

Internal link: For a detailed comparison of compounded vs brand-name tirzepatide, see our article on compounded semaglutide vs Ozempic.

Channel 4: Direct compounding pharmacies

How it works: You obtain a prescription for compounded tirzepatide from your own provider (primary care, endocrinologist, weight-loss specialist). You send the prescription directly to a compounding pharmacy of your choice. The pharmacy prepares the medication and either ships it or makes it available for local pickup.

Cost: $350 to $500 per month. Pricing varies by pharmacy and dose. Some compounding pharmacies offer lower pricing than telehealth platforms because they don't include provider consultation fees, but you're responsible for obtaining the prescription separately.

Speed: 5 to 10 days from prescription submission to delivery or pickup. Compounding pharmacies typically batch-produce common formulations, so turnaround is faster than custom compounds but slower than telehealth platforms with dedicated high-volume partners.

Who uses this channel: Patients who already have a prescriber willing to write for compounded tirzepatide and want to avoid telehealth platform fees. Also used by patients who prefer a specific local compounding pharmacy they trust.

How to find a compounding pharmacy: The International Academy of Compounding Pharmacists (IACP) maintains a directory at iacprx.org. Search by ZIP code and filter for "weight management" or "peptide therapy." Call ahead to confirm they compound tirzepatide and ask whether they're 503A or 503B.

Pros: Potentially lower cost than telehealth if you already have a prescriber, ability to choose a specific trusted pharmacy, option for local pickup in some cases.

Cons: Requires convincing your provider to prescribe compounded medication (many are hesitant), no bundled provider consultation, more steps to coordinate, variable quality across pharmacies.

Channel 5: In-person weight-loss clinics

How it works: You visit a medical weight-loss clinic (standalone or part of a med spa, wellness center, or concierge medicine practice). A provider conducts an in-person evaluation, prescribes tirzepatide (brand-name or compounded depending on the clinic's model), and either dispenses it on-site or sends the prescription to a partner pharmacy.

Cost: $400 to $600 per month for compounded tirzepatide, often bundled with clinic visit fees, body composition analysis, and nutritional counseling. Some clinics charge separately for visits ($150 to $300 per visit) and medication. Brand-name Zepbound at clinics follows the same pricing as retail pharmacies.

Speed: Same-day to 3 days if the clinic stocks compounded tirzepatide on-site. Longer if they send prescriptions to an external pharmacy.

Who uses this channel: Patients who prefer in-person care, want integrated weight-loss support (dietitian, exercise physiologist, behavioral health), or have complex medical histories requiring more hands-on management.

Pros: In-person evaluation and monitoring, integrated support services, immediate access if medication is stocked on-site, relationship continuity with a local provider.

Cons: Higher cost than telehealth, requires local availability (not accessible in many rural areas), often requires ongoing visit fees, less price transparency.

How to find clinics: Search "medical weight loss clinic [your city]" or "GLP-1 clinic near me." The American Board of Obesity Medicine maintains a provider directory at abom.org. Call ahead to ask whether they prescribe tirzepatide, whether it's brand-name or compounded, and what the all-in monthly cost is.

The cost breakdown: insurance vs cash-pay across all five channels

The cost question has two entirely different answers depending on whether you have insurance coverage.

With commercial insurance and prior authorization approval:

• Retail pharmacy: $25 to $150 copay per month (with Lilly savings card, $25)
• Specialty pharmacy: $25 to $150 copay per month (with Lilly savings card, $25)
• Telehealth: Not applicable (no insurance accepted)
• Direct compounding: Not applicable (insurance rarely covers compounded medications)
• Weight-loss clinic: Rarely covered; if covered, $25 to $150 copay

Without insurance or with insurance that doesn't cover GLP-1s for weight loss:

• Retail pharmacy: $1,060 per month (brand-name Zepbound)
• Specialty pharmacy: $1,060 per month (brand-name Zepbound)
• Telehealth: $295 to $450 per month (compounded tirzepatide)
• Direct compounding: $350 to $500 per month (compounded tirzepatide)
• Weight-loss clinic: $400 to $600 per month (compounded tirzepatide)

The math is straightforward: if you have insurance coverage, brand-name Zepbound through retail or specialty pharmacy is cheaper. If you don't, compounded tirzepatide through telehealth is cheaper by a factor of 2 to 3.

The hidden cost: prior authorization time. Patients with insurance often wait 5 to 14 days for prior authorization approval. During that window, you're not on medication. For some patients, the speed advantage of telehealth (3 to 7 days to first dose) outweighs the cost advantage of insurance, especially if prior authorization is denied and you end up paying cash anyway.

The speed comparison: which channel gets you started fastest

Speed matters for two reasons: medical (the sooner you start, the sooner you see metabolic benefits) and psychological (long waits increase dropout rates before treatment even begins).

Time from decision to first injection:

Channel	Fastest possible	Typical	Slowest case
Retail pharmacy (in stock)	Same day	1-2 days	5 days
Retail pharmacy (must order)	2 days	4 days	10 days
Specialty pharmacy	7 days	10 days	21 days
Telehealth + compounding	3 days	5 days	7 days
Direct compounding	5 days	7 days	14 days
Weight-loss clinic (in stock)	Same day	Same day	3 days
Weight-loss clinic (must order)	3 days	5 days	10 days

The fastest option is a weight-loss clinic with on-site inventory: walk in, get evaluated, walk out with medication. The second-fastest is telehealth: complete intake today, receive medication in 3 to 7 days.

The slowest is specialty pharmacy with prior authorization: 7 to 21 days is common, and denials requiring appeals can push timelines to 30+ days.

For patients optimizing for speed, the decision tree is simple: if you want same-day access and have a local clinic, use channel 5. If you want access within a week and prefer virtual care, use channel 3. If you have insurance and are willing to wait for prior authorization, use channel 1 or 2.

When compounded tirzepatide is the better choice than brand-name Zepbound

The default assumption in most medical contexts is that FDA-approved brand-name medications are preferable to compounded alternatives. That assumption breaks down in specific scenarios.

Compounded tirzepatide is the better choice when:

1. You don't have insurance coverage. The $295 to $450 price point for compounded tirzepatide is 60% to 72% lower than the $1,060 brand-name price. The cost difference over 12 months is $7,320 to $9,180.

1. Your insurance requires step therapy. Many plans require trying semaglutide (Ozempic or Wegovy) before approving tirzepatide. If you've tried semaglutide and had intolerable side effects or inadequate response, waiting for step therapy approval can take 30 to 60 days. Compounded tirzepatide bypasses that entirely.

1. You're in the deductible phase. High-deductible health plans (HDHPs) require you to pay full price until you hit your deductible (often $3,000 to $7,000). During that window, you're paying $1,060 per month for brand-name Zepbound anyway. Compounded tirzepatide costs less even without insurance.

1. You need to start immediately. Prior authorization averages 5 to 14 days. Telehealth platforms deliver compounded tirzepatide in 3 to 7 days with no prior authorization required.

1. Your provider won't prescribe brand-name GLP-1s for weight loss. Some primary care providers are hesitant to prescribe brand-name GLP-1s due to cost concerns or lack of familiarity with obesity medicine. Telehealth platforms employ providers who specialize in metabolic health and prescribe routinely.

1. You're on Medicare. Medicare does not cover GLP-1 medications for weight loss under federal law. Brand-name Zepbound costs $1,060 per month out-of-pocket for Medicare patients. Compounded tirzepatide costs $295 to $450.

Brand-name Zepbound is the better choice when:

1. Your insurance covers it with a low copay. If your copay is $25 to $50 per month, brand-name is cheaper than compounded.

1. You prefer FDA-approved medications. Brand-name Zepbound underwent Phase 3 trials with 2,539 patients in SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022). Compounded tirzepatide uses the same active ingredient but is not FDA-approved and has not undergone the same review process.

1. You have a complex medical history. Patients with multiple comorbidities, prior bariatric surgery, or other complicating factors may benefit from the closer monitoring and specialist involvement typical of brand-name prescribing.

1. Your employer or plan specifically requires brand-name. Some plans exclude coverage for compounded medications entirely and audit for off-formulary prescribing.

The choice is not binary. Some patients start with compounded tirzepatide for speed and cost, then switch to brand-name Zepbound once insurance approves. Others do the reverse: start with brand-name through insurance, then switch to compounded when they hit coverage limits or lose insurance.

The FormBlends Access Decision Tree

This is the decision framework we use when patients ask "where should I get tirzepatide?" It's a branching flowchart based on insurance status, speed requirements, and cost tolerance.

Start here: Do you have commercial health insurance?

• Yes → Does your plan cover GLP-1 medications for weight loss?
• Yes → Are you willing to wait 5 to 14 days for prior authorization?
• Yes → Use retail pharmacy (channel 1) or specialty pharmacy (channel 2). Apply for Lilly savings card to reduce copay to $25.
• No → Use telehealth + compounding (channel 3) to start immediately, then switch to insurance-covered brand-name once prior authorization approves.
• No → Are you currently in your deductible period?
• Yes → Use telehealth + compounding (channel 3). You'll pay out-of-pocket either way; compounded is cheaper.
• No → Use telehealth + compounding (channel 3) or direct compounding (channel 4).
• No → Do you have Medicare?
• Yes → Use telehealth + compounding (channel 3). Medicare doesn't cover GLP-1s for weight loss, so brand-name costs $1,060 vs $295 to $450 for compounded.
• No → Do you want same-day access?
• Yes → Find a local weight-loss clinic with on-site inventory (channel 5).
• No → Use telehealth + compounding (channel 3) for best combination of speed and cost.

[Diagram suggestion: Flowchart with decision nodes as described above, color-coded by channel type, with cost and speed annotations on each endpoint]

Regional supply differences: why location still matters in 2026

Despite the rise of telehealth and mail-order, geographic location still affects tirzepatide access in three ways.

1. Local pharmacy stock levels. Urban areas with high GLP-1 demand see more frequent stockouts. A 2025 analysis of pharmacy claims data found that pharmacies in the top 20 metropolitan areas by population had 2.3 times higher stockout rates for tirzepatide than pharmacies in rural areas (Chen et al., Health Affairs, 2025). The paradox: more demand means more frequent ordering, but also more competition for limited supply.

2. State compounding regulations. North Dakota and West Virginia have restrictions that effectively prohibit out-of-state compounding pharmacies from shipping to residents. Patients in those states must use in-state compounding pharmacies (if available) or obtain brand-name Zepbound. Most telehealth platforms do not serve ND or WV for this reason.

3. Provider density. Access to obesity medicine specialists and endocrinologists varies dramatically by region. The American Board of Obesity Medicine reports 7,200 board-certified obesity medicine physicians in the U.S. as of 2026, but 68% practice in just 15 states (California, Texas, Florida, New York, Illinois, Pennsylvania, Ohio, North Carolina, Georgia, Virginia, Washington, Colorado, Arizona, Massachusetts, and Michigan). Patients in other states often rely on primary care providers, who may be less familiar with GLP-1 prescribing, or turn to telehealth.

Prediction: By Q4 2026, the FDA will remove tirzepatide from the drug shortage list. Eli Lilly has expanded manufacturing capacity significantly in 2025 and 2026. Once removal happens, compounding pharmacies will have a 60-day wind-down period under FDA guidance. Telehealth platforms will either pivot to brand-name distribution partnerships or exit the tirzepatide market. Patients currently on compounded tirzepatide should plan for a transition to brand-name or alternative GLP-1s in late 2026 or early 2027.

The case against rushing to start: when slower access is better

Most of this article optimizes for speed and cost. Here's the steelman for the opposite view: sometimes the slower, more expensive channel is the right choice.

When you should NOT prioritize speed:

1. You have untreated or poorly controlled comorbidities. Patients with uncontrolled hypertension, untreated sleep apnea, or active gallbladder disease should have those conditions stabilized before starting a GLP-1. The rapid weight loss can worsen gallstone formation, and the blood pressure effects of GLP-1s can be unpredictable in patients with labile hypertension. A slower process with in-person evaluation catches these issues.

1. You have a history of disordered eating. GLP-1 medications suppress appetite powerfully. In patients with a history of restrictive eating disorders, this can trigger relapse. The slower pace of in-person weight-loss clinics (channel 5) allows for integrated behavioral health screening that telehealth platforms often miss.

1. You're on multiple other medications with interaction potential. Tirzepatide slows gastric emptying, which can affect absorption of oral medications. Patients on thyroid hormone, seizure medications, or certain psychiatric medications need closer monitoring during titration. Specialty pharmacies (channel 2) provide medication therapy management that catches interactions.

1. You're using this as a last resort after multiple failed attempts. If you've tried and stopped three other weight-loss medications, the pattern suggests either unrealistic expectations or inadequate support. Paying more for a weight-loss clinic (channel 5) with integrated coaching may be the difference between success and another failed attempt.

1. You have a strong preference for FDA-approved medications. This is a values question, not a medical one. Some patients are uncomfortable with compounded medications regardless of cost savings. That preference is valid. Use channels 1 or 2.

The faster, cheaper option is not always the better option. The right channel is the one that matches your medical complexity, support needs, and values.

FAQ

Where can I get Zepbound without insurance? You can get brand-name Zepbound at any retail pharmacy for $1,060 per month cash price, or you can get compounded tirzepatide through telehealth platforms for $295 to $450 per month. Telehealth is faster (3 to 7 days) and significantly cheaper for uninsured patients.

Can I get Zepbound at CVS or Walgreens? Yes, if you have a prescription. CVS and Walgreens stock Zepbound, but availability varies by location. Call ahead to confirm stock. If they need to order it, expect 2 to 5 days. With insurance and prior authorization, copays are typically $25 to $150. Without insurance, the cash price is $1,060 per month.

How long does it take to get Zepbound from a pharmacy? Same-day if the pharmacy has it in stock. If they need to order it, 2 to 5 business days is typical. Specialty pharmacies take 7 to 14 days due to prior authorization processing. Telehealth platforms with compounded tirzepatide deliver in 3 to 7 days.

Is compounded tirzepatide the same as Zepbound? Both contain the same active ingredient (tirzepatide), but they're not interchangeable. Zepbound is FDA-approved and manufactured by Eli Lilly. Compounded tirzepatide is prepared by state-licensed compounding pharmacies and is not FDA-approved. Compounded versions are legal while tirzepatide remains on the FDA drug shortage list.

Does Medicare cover Zepbound? No. Medicare does not cover GLP-1 medications for weight loss under federal law. Medicare patients pay $1,060 per month for brand-name Zepbound or $295 to $450 per month for compounded tirzepatide through telehealth platforms.

Can I get Zepbound through telehealth? Most telehealth platforms offer compounded tirzepatide, not brand-name Zepbound. A few platforms have partnerships to prescribe brand-name Zepbound if you have insurance, but the majority operate on a cash-pay compounded model. Expect 3 to 7 days from consultation to delivery.

What's the cheapest way to get Zepbound? With commercial insurance, prior authorization approval, and the Lilly savings card: $25 per month. Without insurance: compounded tirzepatide through telehealth at $295 to $450 per month. Brand-name Zepbound without insurance costs $1,060 per month.

Do I need a prescription for Zepbound? Yes. Zepbound and compounded tirzepatide are prescription-only medications. Telehealth platforms provide the prescription as part of their service. Retail pharmacies require you to bring a prescription from your own provider.

How do I know if my insurance covers Zepbound? Call the member services number on your insurance card and ask whether GLP-1 medications for weight loss are covered, what the prior authorization requirements are, and what your copay will be. You can also check your plan's formulary online. Most commercial plans cover Zepbound with prior authorization; Medicare and Medicaid do not.

Can I switch from compounded tirzepatide to brand-name Zepbound? Yes. The dosing is equivalent, so you can switch at the same dose level. Coordinate the timing so you don't have a gap in treatment. Some patients start with compounded for speed, then switch to brand-name once insurance approves.

Where can I find a weight-loss clinic that prescribes Zepbound? Search "medical weight loss clinic [your city]" or use the American Board of Obesity Medicine directory at abom.org. Call ahead to ask whether they prescribe tirzepatide, whether it's brand-name or compounded, what the total monthly cost is, and whether they have on-site inventory.

Is Zepbound available at Costco or Sam's Club? Yes, if you have a prescription. Costco and Sam's Club pharmacies often have slightly lower cash prices than CVS or Walgreens (around $1,020 vs $1,060), but you need a membership. Stock availability is similar to other retail pharmacies.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Smith JL et al. GLP-1 Receptor Agonist Availability in Community Pharmacies. Journal of Managed Care Pharmacy. 2025.
4. Chen R et al. Geographic Variation in GLP-1 Medication Access and Stockout Rates. Health Affairs. 2025.
5. FDA Drug Shortage Database. Tirzepatide injection. Updated April 2026.
6. FDA Guidance for Industry. Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2024.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2023.
8. Eli Lilly and Company. Zepbound Prescribing Information. 2023.
9. American Board of Obesity Medicine. Diplomate Directory. 2026.
10. International Academy of Compounding Pharmacists. Find a Compounding Pharmacy Tool. 2026.
11. National Community Pharmacists Association. GLP-1 Medication Access Survey. 2025.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. CVS, Walgreens, and Kroger are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.